JP2011507896A5 - - Google Patents

Download PDF

Info

Publication number
JP2011507896A5
JP2011507896A5 JP2010539862A JP2010539862A JP2011507896A5 JP 2011507896 A5 JP2011507896 A5 JP 2011507896A5 JP 2010539862 A JP2010539862 A JP 2010539862A JP 2010539862 A JP2010539862 A JP 2010539862A JP 2011507896 A5 JP2011507896 A5 JP 2011507896A5
Authority
JP
Japan
Prior art keywords
compound according
pyrrolo
phenylamino
pyrimidine
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010539862A
Other languages
English (en)
Japanese (ja)
Other versions
JP5710269B2 (ja
JP2011507896A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/087626 external-priority patent/WO2009082687A1/en
Publication of JP2011507896A publication Critical patent/JP2011507896A/ja
Publication of JP2011507896A5 publication Critical patent/JP2011507896A5/ja
Application granted granted Critical
Publication of JP5710269B2 publication Critical patent/JP5710269B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010539862A 2007-12-21 2008-12-19 アザインドリジン類と使用方法 Expired - Fee Related JP5710269B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1594207P 2007-12-21 2007-12-21
US61/015,942 2007-12-21
PCT/US2008/087626 WO2009082687A1 (en) 2007-12-21 2008-12-19 Azaindolizines and methods of use

Publications (3)

Publication Number Publication Date
JP2011507896A JP2011507896A (ja) 2011-03-10
JP2011507896A5 true JP2011507896A5 (https=) 2012-01-19
JP5710269B2 JP5710269B2 (ja) 2015-04-30

Family

ID=40352017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010539862A Expired - Fee Related JP5710269B2 (ja) 2007-12-21 2008-12-19 アザインドリジン類と使用方法

Country Status (12)

Country Link
US (1) US8486963B2 (https=)
EP (1) EP2220092B1 (https=)
JP (1) JP5710269B2 (https=)
KR (1) KR20100099185A (https=)
CN (1) CN101945875B (https=)
AU (1) AU2008340247B2 (https=)
BR (1) BRPI0819505A2 (https=)
CA (1) CA2708176A1 (https=)
ES (1) ES2387707T3 (https=)
IL (1) IL206125A (https=)
NZ (1) NZ586575A (https=)
WO (1) WO2009082687A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
KR20130016041A (ko) * 2011-08-04 2013-02-14 재단법인 의약바이오컨버젼스연구단 신규한 아닐린 유도체 및 이의 용도
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US10570019B2 (en) * 2014-06-03 2020-02-25 Gaia Institute Of Environment Technology Inc. Amorphous silicon for use in foods, drugs, cosmetics and feed, and production method and production device thereof
WO2017180581A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
MX2019013562A (es) 2017-05-19 2020-08-03 Nflection Therapeutics Inc Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
US11161845B2 (en) 2017-05-19 2021-11-02 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
AU2018329925B2 (en) 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
CR20200554A (es) 2018-05-17 2021-01-12 Bayer Ag Derivados sustituidos de la carboxamida dihidropirazolo pirazina
AU2019383311B2 (en) 2018-11-20 2024-12-05 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
US12466818B2 (en) 2018-11-20 2025-11-11 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2026019990A1 (en) 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JPH08176070A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp ジデプシド誘導体及びpi3キナーゼ阻害剤
JPH08175990A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Pi3キナーゼ阻害剤とその製造法
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en) 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO1998030566A1 (en) 1997-01-06 1998-07-16 Pfizer Inc. Cyclic sulfone derivatives
EP0977733B1 (en) 1997-02-03 2003-09-03 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
DE69837529T2 (de) 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
AU730248B2 (en) 1997-08-08 2001-03-01 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
DK1004578T3 (da) 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
CZ301689B6 (cs) 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
SI1255752T1 (sl) 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
JP2001247477A (ja) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd 抗腫瘍剤
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
DE60203260T2 (de) 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
US6605056B2 (en) 2001-07-11 2003-08-12 Scimed Life Systems, Inc. Conformable balloon
US20040242545A1 (en) 2001-07-26 2004-12-02 Santen Phamaceutical Co., Ltd. Remedy for glaucoma comprising as the active ingredient compound having p13 kinase inhibitory effect
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
IL160915A0 (en) 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
AU2002349912A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6894055B2 (en) 2001-10-24 2005-05-17 Iconix Pharmaceuticals Inc. Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase
AU2002356871A1 (en) 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
JP2006500327A (ja) 2002-07-10 2006-01-05 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 精子の運動性を増大させるための化合物の使用
CN1681811B (zh) 2002-07-10 2010-05-26 默克雪兰诺有限公司 唑烷酮-乙烯基稠合的-苯衍生物
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
JP2004203748A (ja) * 2002-12-24 2004-07-22 Kissei Pharmaceut Co Ltd 新規なイミダゾ[1,2−c]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
AU2004249498B2 (en) * 2003-06-20 2009-11-19 Ucb Pharma S.A. Thienopyridone derivatives as kinase inhibitors
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2008070740A1 (en) 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use

Similar Documents

Publication Publication Date Title
JP2011507896A5 (https=)
JP2009504763A5 (https=)
JP2011526924A5 (https=)
JP2011526926A5 (https=)
JP2010077141A5 (https=)
JP2011529070A5 (https=)
CN117597327A (zh) 药物制剂
JP2007522098A5 (https=)
JP2011006480A5 (https=)
JP2010530881A5 (https=)
JP2012500260A5 (https=)
JP2006523216A5 (https=)
JP2006524660A5 (https=)
JP2013514980A5 (https=)
JP2004516314A5 (https=)
JP2009536660A5 (https=)
JP2013508382A5 (https=)
JP2006503850A5 (https=)
HRP20211762T1 (hr) Derivati benzoksaborola za liječenje bakterijskih infekcija
JP2007520452A5 (https=)
JP2008514718A5 (https=)
JP2013518036A5 (https=)
JP2011517697A5 (https=)
JP2011509302A5 (https=)
JP2013503881A5 (https=)